De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections

By Masterton Robert G.   Casamayor Montserrat   Musingarimi Primrose   van Engen Anke   Zinck Raymund   Odufowora-Sita Olatunji   Odeyemi Isaac A. O.  

Journal of Medical Economics, Vol. 16, Iss. 11, 2013-11 ,pp. : 1344-1356

Informa Healthcare

Access to resources Recommend Favorite

Comments and reply on: Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

By Currie Craig J.   McEwan Phil   Poole Chris   Valentine William J.   Palmer Andrew J.   Lammert Morten   Nicklasson Lars   Foos Volker   Roze Stéphane  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 967-969

Informa Healthcare

Access to resources Recommend Favorite

Supplement: Trends in invasive Candida infections and their treatment: focus on echinocandins

By  

Current Medical Research and Opinion, Vol. 25, Iss. 7, 2009-07 ,pp. : 1729-1762

Informa Healthcare

Access to resources Recommend Favorite

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

By Valentine William J.   Palmer Andrew J.   Lammert Morten   Nicklasson Lars   Foos Volker   Roze Stéphane  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 2063-2071

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK

By McEwan Phil   Poole Chris D.   Tetlow Tony   Holmes Paul   Currie Craig J.  

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-02 ,pp. : 21-31

Informa Healthcare

Access to resources Recommend Favorite